Palogic Value Management L.P. Has $2.72 Million Stake in Aspen Aerogels, Inc. $ASPN

Key Points

• Palogic Value Management L.P. increased its stake in Aspen Aerogels, Inc. by 226.9% during Q1, now holding 425,000 shares valued at approximately $2.72 million.
• Aspen Aerogels reported a revenue of $78.02 million for its most recent quarter, exceeding analysts' estimates, despite a 33.8% decrease year-over-year.
• Barclays lowered its rating on Aspen Aerogels from "equal weight" to "underweight" but raised the price target from $7.00 to $16.00, while the average target price is currently set at $19.50.

Palogic Value Management L.P. raised its position in Aspen Aerogels, Inc. (NYSE:ASPN - Free Report) by 226.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 425,000 shares of the construction company's stock after purchasing an additional 295,000 shares during the period. Aspen Aerogels accounts for approximately 1.2% of Palogic Value Management L.P.'s portfolio, making the stock its 28th largest position. Palogic Value Management L.P. owned 0.52% of Aspen Aerogels worth $2,716,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD increased its stake in shares of Aspen Aerogels by 38.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 42,451 shares of the construction company's stock valued at $505,000 after acquiring an additional 11,688 shares in the last quarter. Northern Trust Corp increased its stake in shares of Aspen Aerogels by 13.7% in the 4th quarter. Northern Trust Corp now owns 641,050 shares of the construction company's stock valued at $7,616,000 after acquiring an additional 77,364 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Aspen Aerogels by 17.8% in the 4th quarter. Ameriprise Financial Inc. now owns 524,501 shares of the construction company's stock valued at $6,231,000 after acquiring an additional 79,122 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Aspen Aerogels by 645.4% in the 4th quarter. BNP Paribas Financial Markets now owns 135,584 shares of the construction company's stock valued at $1,611,000 after acquiring an additional 117,395 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in shares of Aspen Aerogels by 37.0% in the 4th quarter. Deutsche Bank AG now owns 415,391 shares of the construction company's stock valued at $4,935,000 after acquiring an additional 112,241 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Aspen Aerogels Stock Performance

Shares of ASPN stock opened at $6.75 on Tuesday. The firm has a market capitalization of $555.52 million, a PE ratio of -1.77 and a beta of 2.65. The firm has a fifty day simple moving average of $7.10 and a two-hundred day simple moving average of $6.50. The company has a current ratio of 3.98, a quick ratio of 3.31 and a debt-to-equity ratio of 0.34. Aspen Aerogels, Inc. has a 12 month low of $4.16 and a 12 month high of $30.24.

Aspen Aerogels (NYSE:ASPN - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The construction company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.08. The firm had revenue of $78.02 million for the quarter, compared to the consensus estimate of $72.53 million. Aspen Aerogels had a negative net margin of 78.53% and a positive return on equity of 2.92%. The business's revenue for the quarter was down 33.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.21 EPS. Aspen Aerogels has set its FY 2025 guidance at -3.860--3.730 EPS. Analysts forecast that Aspen Aerogels, Inc. will post 0.17 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ASPN has been the subject of several research analyst reports. Barclays lowered shares of Aspen Aerogels from an "equal weight" rating to an "underweight" rating and lifted their price objective for the company from $7.00 to $16.00 in a research note on Monday, August 11th. Canaccord Genuity Group lowered their price objective on shares of Aspen Aerogels from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $19.50.

Insider Transactions at Aspen Aerogels

In other Aspen Aerogels news, CAO Santhosh P. Daniel sold 4,410 shares of Aspen Aerogels stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $7.31, for a total transaction of $32,237.10. Following the transaction, the chief accounting officer directly owned 19,879 shares of the company's stock, valued at $145,315.49. The trade was a 18.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.40% of the stock is owned by corporate insiders.

Aspen Aerogels Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.